References
- National diabetes statistics report, 2017. Atlanta, GA Centers Dis. Control Prev. US Dept Heal. Hum. Serv. 2017;41:917–928.
- Yang W, Dall TM, Beronjia K, et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
- Iglay K, Hannachi H, Howie PJ, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016;32(7):1243–1252.
- Bashier A, Bin Hussain A, Abdelgadir E, et al. Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr. 2019;11:80. Available from:/pmc/articles/PMC6761728/?report = abstract.
- Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–228. Available from: https://pubmed.ncbi.nlm.nih.gov/31853556/.
- Association AD. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98–S110.
- Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Associ. Eur Heart J. 2020;41:255–323. Available from: www.escardio.org/guidelines.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1911303.
- Merck and Pfizer’s SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. [Internet]. 2020. https://www.merck.com/news/merck-and-pfizers-sglt2-inhibitor-steglatro-ertugliflozin-meets-primary-endpoint-in-vertis-cv-trial-for-patients-with-type-2-diabetes-and-atherosclerotic-cardiovascular-disease/.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
- Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)z. Kidney Int. 2005;67(6):2089–2100.
- American Diabetes Association. Glycemic targets: standards of medical care in Diabetesd2018. Diabetes Care 2018;41:S55–S64.
- Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. J Diabetes. 2018;10(3):192–199.
- Pantalone KM, Hobbs TM, Wells BJ, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care. 2015;3(1):e000093. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513350/.
- Giugliano D, Longo M, Maiorino MI, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract. 2020;162:108114. Available from: https://pubmed.ncbi.nlm.nih.gov/32165164/.
- Assari S, Lee DB, Nicklett EJ, et al. Racial Discrimination in health care is associated with worse glycemic control among black men but not black women with type 2 diabetes. Front Public Health. 2017;5:235
- Fan T, Koro CE, Fedder DO, et al. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002. Diabetes Care. 2006;29(8):1924–1925.
- Mishriky BM, Powell JR, Wittwer JA, et al. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(10):2274–2283. [cited 2020 Aug 6]. Available from: https://pubmed.ncbi.nlm.nih.gov/31168889/.
- Ajmera M, Raval A, Zhou S, et al. A real-world observational study of time to treatment intensification among elderly patients with inadequately controlled type 2 diabetes mellitus. J Manag Care Spec Pharm. 2015;21(12):1184–1193. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760631/.
- Thein D, Christiansen MN, Mogensen UM, et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19:107. Available from: https://pubmed.ncbi.nlm.nih.gov/32631337/.
- Patorno E, Pawar A, Bessette LG, et al. Effectiveness and safety of Empagliflozin in routine care patients: interim results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes. 2020; 69(Supplement 1):134-LB.
- Patorno E, Pawar A, Bessette LG, et al. Cardiovascular outcomes in older adults initiating Empagliflozin vs. DPP-4 inhibitors and GLP-1 receptor agonists: a subgroup analysis from the EMPRISE study. Diabetes. 2020; 69(Supplement 1):133-LB.
- Casagrande SS, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;36(8):2271–2279. Available from: https://care.diabetesjournals.org/content/36/8/2271.
- Nathan DM, McGee P, Steffes MW, et al. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63(1):282–290. Available from: https://pubmed.ncbi.nlm.nih.gov/23990364/.
- Svensson E, Baggesen LM, Johnsen SP, et al. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: Population-based cohort study of 24,752 metformin initiators. Dia Care. 2017;40(6):800–807. Available from: https://pubmed.ncbi.nlm.nih.gov/28404659/.
- France EF, Wyke S, Gunn JM, et al. Multimorbidity in primary care: a systematic review of prospective cohort studies. Br J Gen Pract. 2012;62(597):e297–e307. Available from: https://bjgp.org/content/62/597/e297.
- Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269–2276. Available from: https://jamanetwork.com/.
- Lin PJ, Kent DM, Winn A, et al. Multiple chronic conditions in type 2 diabetes mellitus: prevalence and consequences. Am J Manag Care. 2015;21(1):e23–e34.
- Kathe N, Hayes CJ, Bhandari NR, et al. Assessment of reliability and validity of SF-12v2 among a diabetic population. Value Health. 2018;21(4):432–440.